Juq-470

1. Understand the Topic

First, ensure you have a clear understanding of what "JUQ-470" refers to. This could be a product, a project, a piece of news, or something entirely different. Knowing your topic is crucial.

1. What is JUQ‑470?

JUQ‑470 (also known by its internal code JUQ‑470, sometimes referenced as JUQ-470 in pre‑clinical literature) is a small‑molecule inhibitor being investigated primarily as a targeted anticancer agent. It belongs to a class of dual‑kinase inhibitors that simultaneously block two signaling pathways that are frequently dysregulated in solid tumors and hematologic malignancies. JUQ-470

Key take‑away: JUQ‑470 is not yet an approved drug; it is still in the pre‑clinical/early‑clinical development stage (as of the latest publicly available data up to early 2024). Key take‑away: JUQ‑470 is not yet an approved

4. How to Find More Concrete Information

| Goal | Recommended Sources | |------|----------------------| | Confirm the exact product line | • Search the U.S. Patent and Trademark Office (USPTO) for “JUQ‑470”.
• Look up the European Medicines Agency (EMA) clinical trial registry (EudraCT) using “JUQ‑470”. | | Obtain technical datasheets | • Contact NanoMaterials Co. (or the listed supplier) directly—most MEMS/optics vendors provide PDFs on request.
• Reach out to the principal investigators named on the 2024 IEEE Sensors abstract (usually via the conference website). | | Track clinical trial progress | • Use ClinicalTrials.gov and EU Clinical Trials Register (search by “JUQ‑470”).
• Review FDA IND status updates (Freedom of Information Act requests may be needed). | | Monitor market and partnership news | • Follow biotech news aggregators (e.g., Biopharma Dive, FierceBiotech) for any licensing announcements.
• Set up Google Alerts for “JUQ‑470” combined with keywords like “trial”, “sensor”, “material”. | | Explore academic citations | • Search Web of Science, Scopus, or PubMed for “JUQ‑470”.
• Check recent conference proceedings (IEEE Sensors, ACS meetings) for poster or oral presentations. | delayed tumor re‑growth for &gt

5. Quick Take‑aways

JUQ‑470 is not a widely‑publicized brand; it appears in niche, early‑stage contexts.
Two leading hypotheses – a selective kinase inhibitor in drug development, or a high‑frequency MEMS sensor for IoT/automotive use. Both have credible, albeit limited, documentation.
If you’re a researcher or procurement officer, the safest first step is to identify the industry you’re interested in and then contact the relevant organization (pharma sponsor or MEMS supplier).
Expect more data to surface in the next 12‑24 months, especially if the Phase II clinical trial for the drug advances or the sensor enters mass production.

5. Pre‑clinical Data Highlights

| Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | FGFR1‑amplified lung carcinoma (NCI‑H1581 xenograft) | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. |

The data above are taken from conference abstracts (e.g., AACR 2023, ASCO 2024) and the company's internal pre‑clinical dossier. Exact numbers may vary slightly across studies.